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AbstrACt
Introduction Cytomegalovirus (CMV) anterior uveitis is a 
recognised cause of anterior uveitis in immunocompetent 
patients and is preventable cause of vision loss. Ocular 
sequelae include corneal endothelial damage which can 
cause corneal oedema and failure, as well as glaucoma. 
Recurrences of inflammation are common and therefore 
patients are often exposed to long- term therapy. Oral 
therapy is available in the form of valganciclovir, although 
with the caveat of systemic side effects such as bone 
marrow suppression and renal failure necessitating 
regular interval laboratory monitoring. Recent reports have 
demonstrated that topical 2% ganciclovir solution may 
offer promising treatment outcomes in patients with CMV 
anterior uveitis with superior safety, cost- effectiveness 
and convenience profiles. An investigation into the relative 
equipoise of these therapies is warranted for these 
reasons.
Methods and analysis The Systemic and Topical Control 
of Cytomegalovirus Anterior uveitis: Treatment Outcomes 
(STACCATO) trial is designed as a multicentre, block 
randomised by site, double- masked, placebo- controlled 
trial comparing the efficacy of oral valganciclovir, 2% 
topical ganciclovir and placebo in treating PCR- proven 
CMV anterior uveitis. Participant clinical evaluation 
will occur at three study time points by a masked 
study ophthalmologist over a 28- day period to assess 
resolution of ocular inflammation (secondary outcome). 
A control group will provide additional information about 
the possible impact that the infected host’s immune 
response may play in controlling local viral replication. The 
primary analysis is an analysis of covariance (three arms) 
correcting for baseline to compare quantitative CMV viral 
load in the anterior chamber (AC) aqueous fluid before and 
7 days after treatment.
Ethics and dissemination The University of California 
San Francisco Committee on Human Research and the 
Khon Kaen University Institutional Review Board have given 
ethical approval. The results of this trial will be presented 
at local and international meetings and submitted for peer- 
reviewed journals for publication.
trial registration number NCT03576898.
IntroduCtIon
Cytomegalovirus (CMV) has been recognised 
as an important cause of posterior retinitis in 
patients with HIV/AIDS, particularly prior to 
the introduction of highly active antiretroviral 
therapy. However, CMV is now being impli-
cated in immunocompetent individuals as a 
strengths and limitations of this study
 ► This randomised clinical trial compares both clinical 
and quantitative microbiological outcomes of cyto-
megalovirus treatment as opposed to solely clinical 
response.
 ► Baseline and end- line quantitative PCR viral loads 
from all sites that will be included in analysis are 
processed at the same laboratory, ensuring a uni-
form assessment of reduction in viral load.
 ► This is a multicentre clinical trial that includes three 
sites in Asia where the disease is most prevalent.
 ► Our limited sample size may not allow detection 
of the smallest meaningful difference between the 
treatments.
 ► Adherence is mainly assessed via self- report and 
may not accurately reflect treatment administration.
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1. I think that oral valganciclovir is an effective medication to treat CMV 
anterior uveitis
0 (0%) 8 (11.8%) 36 (52.9%) 24 (35.3%)
2. I think that topical ganciclovir 2% eye drops is an effective medication 
to treat CMV anterior uveitis
1 (1.5%) 11 (16.2%) 33 (48.5%) 23 (33.82%)
3. I think that oral valganciclovir is a safe medication to treat short term 
ocular inflammation related to CMV anterior uveitis
0 (0%) 11 (16.2%) 36 (52.9%) 21 (30.9%)
4. I think that oral valganciclovir is a safe medication to treat long- term 
ocular inflammation and prevent recurrences of CMV anterior uveitis
2 (2.9%) 20 (29.4%) 33 (48.5%) 13 (19.1%)
5. I think that topical ganciclovir eyedrops are a safe medication to treat 
short- term ocular inflammation related to CMV anterior uveitis
1 (1.5%) 8 (11.8%) 28 (41.2%) 31 (45.6%)
6. I think that topical ganciclovir eyedrops are a safe medication to treat 
long- term ocular inflammation and prevent recurrences of CMV anterior 
uveitis
1 (1.5%) 17 (25.0%) 31 (45.6%) 19 (27.9%)
7. I think that there is a benefit to treating CMV with long- term therapy 
(beyond 6 months)
1 (1.5%) 8 (11.8%) 26 (38.2%) 33 (48.5%)
CMV, cytomegalovirus.
cause of anterior uveitis.1–4 Definitive diagnosis requires 
laboratory diagnosis, such as directed PCR.5
CMV anterior uveitis is a preventable cause of vision 
loss. It can cause damage to the corneal endothelial 
cells, which can lead to oedema, failure and, ultimately, 
requirement for corneal transplant.6–9 CMV can recur in 
transplanted grafts, necessitating further surgeries and 
complications.10–14 Additionally, recurrences of inflam-
mation in CMV anterior uveitis can be associated with 
glaucoma, which can cause irreversible blindness if not 
appropriately managed.15–17
While CMV anterior uveitis is typically characterised by 
recurrent bouts of inflammation, it is unknown whether 
each recurrence is mediated by active viral replication or 
a sterile immune response. Consequently, patients may be 
prescribed frequent oral or topical antiviral therapy. An 
understanding of the most effective treatment strategy for 
CMV anterior uveitis will help inform future studies inves-
tigating ways of decreasing recurrences of inflammation 
in this condition.
One option for the management of CMV anterior 
uveitis is oral valganciclovir 900 mg two times per day.18 19 
Prevention of recurrent inflammation in CMV anterior 
uveitis has been with valganciclovir 450 mg two times 
per day.18 19 Oral valganciclovir can be associated with 
serious systemic side effects including renal failure and 
bone marrow suppression, necessitating regular interval 
laboratory monitoring. Topical ganciclovir 2% has also 
been used to treat and prevent recurrences of CMV ante-
rior uveitis.20–22 Topical therapy is attractive as it does 
not require laboratory monitoring, although ocular side 
effects including corneal epitheliopathy and conjuncti-
vitis could preclude long- term use.23 24 Thus, comparing 
oral valganciclovir 900 mg two times per day to topical 
ganciclovir 2% six times per day has equipoise in the 
uveitis/cornea specialist.
To gain insight into preferred practice patterns for the 
treatment of CMV anterior uveitis, we surveyed attendees 
of the Biennial Chulalongkorn- Khon Kaen- Proctor- UCSF 
(CKPU) meeting in Bangkok, Thailand, on 5 March 
2019. Survey questions were provided in a Likert scale, 
multiple- choice format with participants asked about 
their agreeability on seven statements. Answer choices 
varied from 1 to 4; 1 representing ‘strongly disagree’, 2 
representing ‘somewhat disagree’, 3 representing ‘some-
what agree’ and 4 representing ‘strongly agree’. Sixty- 
eight faculty level physicians responded to our survey, 5 
practising in North America and 63 practising in Asia. 
Results are summarised in table 1. Physician prefer-
ence for treatment medication of CMV anterior uveitis 
in presented in table 2. The results demonstrate that a 
consensus regarding the best treatment for CMV anterior 
uveitis is not yet established.
Some cases of CMV anterior uveitis have been noted 
to resolve without antiviral treatment.25 In this setting, 
having a trial in which oral valganciclovir is compared 
with topical ganciclovir, and including a control group 
where no antiviral was used would provide additional 
information about the possible impact that the infected 
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1. The medication I am most likely to use to treat CMV anterior uveitis 
is…
25 (36.8%) 39 (57.4%) 4 (5.88%)
2. If cost were not an issue my preferred medication to treat CMV 
anterior uveitis would be…
39 (56.5%) 27 (39.1%) 1 (1.5%)
CMV, cytomegalovirus.
Table 3 Timeline of major study procedures
Examination visit Procedures
Prestudy visit (exam #0)—
routine care appointment
 ► Clinical eye examination suggests a viral aetiology
 ► AC paracentesis is performed to establish a viral aetiology
 – Half of fluid will be used for in- house directed PCR for HSV, VZV and CMV
 – At least 50 μL of fluid will be preserved and used for quantitative CMV PCR to be conducted 
at a single US laboratory in eligible participants
 ► Laboratory screening orders (CBC, chemistry panel, pregnancy test, HIV status)
 ► Patients will be prescribed topical corticosteroid (prednisolone acetate 1%) to be used one 
drop in affected eye four times per day (this is typical standard of care)
 ► Patients requiring management of elevated IOP will be prescribed IOP- lowering medication 
according to treating ophthalmologist’s discretion and best medical judgement
Exam #1 (day 1 of study (7 
days after exam #0))
 ► Review of results of in- house CMV PCR and laboratory results
 ► Consent, enrolment, randomisation to treatment arm if participants meet eligibility criteria
 ► Treatment initiation
 ► Clinical eye examination (in the following order, VA, slit lamp examination of anterior segment, 
IOP)
 ► Endothelial cell morphology and density using specular microscopy or confocal microscopy
Exam #2 (day 7 of study)  ► Clinical eye examination (in the following order, VA, slit lamp examination of anterior segment, 
IOP)
 ► AC paracentesis #2
 ► Laboratory monitoring orders (CBC, Cr, BUN)
Exam #3 (day 28 of study)  ► Clinical eye examination (in the following order, VA, slit lamp examination of anterior segment, 
IOP)
 ► Endothelial cell density using specular microscopy or confocal microscopy
 ► Laboratory monitoring orders (CBC, Cr, BUN)
AC, anterior chamber; BUN, blood urea nitrogen; CBC, complete blood count; CMV, cytomegalovirus; Cr, creatinine; HSV, herpes simplex 
virus; IOP, intraocular pressure; VA, visual acuity; VZV, varicella- zoster virus.
ophthalmologist- masked, placebo- controlled trial 
comparing the efficacy of oral valganciclovir and 2% 
topical ganciclovir in treating PCR- proven CMV ante-
rior uveitis. Study participants will be block- randomised 
with 1:1:1 allocation into the three study treatment arms. 
Participants will return to clinic for three study evalua-
tions by a masked study ophthalmologist over a 28- day 
period at which point they will be assessed for resolu-
tion of ocular inflammation. All groups will receive their 
assigned treatment for 28 days. An objective measure of 
treatment efficacy will be assessed via biological samples 
of AC aqueous fluid before and 7 days after treatment. 
An overview of study procedures and study timeline is 
provided in table 3. We used the Standard Protocol Items: 
Recommendations for Interventional Trials checklist 
when writing our protocol.26
specific aims and outcomes
The specific aims of this trial are (1) to assess reduc-
tion in CMV viral load by treatment (as measured by 
log10- transformed quantitative viral load pretreatment 
compared with 7 days after treatment and (2) to assess the 
proportion of participants achieving clinical quiescence 
after 7 and 28 days of treatment. As a nested observational 
aim within our primary aim, we will evaluate the effect of 
topical corticosteroid started prior to enrolment on viral 
load yield by directed quantitative PCR. The research 
hypothesis for this study is that oral valganciclovir therapy 
will demonstrate the greatest efficacy in treating CMV 
anterior uveitis compared with 2% topical ganciclovir and 
placebo therapy.
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Table 4 Study participant inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
 ► CMV positivity by directed PCR from an anterior chamber 
paracentesis specimen conducted at any time in the past
 ► Active anterior uveitis using Standardisation of Uveitis 
Nomenclature (SUN) Working group with clinical impression 
of CMV as the etiologic agent
 – ≥1+ anterior chamber cell AND/OR
 – Other signs consistent with active inflammation, such 
as elevated IOP, corneal oedema and/or active keratic 
precipitates (KPs)
 ► Participant willingness to use an acceptable method of 
contraception during the study period (ie, pharmacologic, 
barrier methods or abstinence).
 ► Participants <20 years of age
 ► Inactive anterior uveitis
 ► Active intermediate or posterior inflammation (involvement 
of vitreous, choroid or retina)
 ► Participants who have received antiviral therapy <14 days 
prior to enrolment
 ► Participants who have received periocular or intraocular 
corticosteroid injection <8 weeks prior to enrolment
 ► Current use of oral corticosteroids
 ► Immunocompromised participants (primary or secondary 
immunodeficiency disorders)
 ► Prior immunosuppressive therapy in the past 3 months
 ► Directed PCR testing positive for HSV or VZV
 ► Plans to conceive during the study period, pregnant or 
breastfeeding mothers (blood or urine pregnancy test for all 
females of childbearing age is mandatory within 4 weeks 
prior to enrolment)
 ► Complete blood count with white blood cell, absolute 
neutrophil or platelet count lower than the lower limit of 
reference laboratory normal
 ► Blood urea nitrogen or creatinine above the upper limit of 
reference laboratory normal
 ► Recent ocular surgery within the past 30 days or planned 
surgery within the next 45 days
 ► Systemic autoimmune disease or ocular condition (besides 
anterior uveitis) anticipated to dictate or alter treatment 
course
CMV, cytomegalovirus; HSV, herpes simplex virus; VZV, varicella- zoster virus.
setting and eligibility
The seroprevalence of CMV varies geographically. In East 
Asia, it estimated to be as high as 87%–100%, whereas 
in Western countries, it is between 51.5% and 54.4%.27–29 
For comparative purposes, four tertiary academic centres 
located in three countries will be included, one in the 
USA, two in Thailand and one in Taiwan.
Participants must provide written, informed consent 
before any study procedures can occur (see online supple-
mentary appendix 1 for a sample informed consent). 
Study inclusion and exclusion criteria are outlined in 
table 4.
recruitment
Each study centre will screen subjects independently 
adhering to the inclusion and exclusion criteria outlined. 
Patients who are found to be CMV positive by in- house 
PCR and who meet eligibility criteria will be approached 
about participating in the study. Participants who have a 
history of previously diagnosed CMV anterior uveitis are 
also eligible to participate in the study. However, like other 
participants, their participation in the trial would require 
that they agree to an anterior chamber (AC) paracentesis 
to confirm that their current flare has demonstrable CMV 
present and to quantify the current flare’s viral load to 
which it would be compared at 7 days post- randomisation. 
Participant enrolment and project activities are planned 
to begin in October 2019 and end August 2021.
Assignment of intervention
Competitive block (of 3 and 6) randomisation of the 
participants, stratified by site will ensure that an equal 
number of participants at each site are randomised to 
study arms in a 1:1:1 ratio, not necessarily enrolling an 
equal number of participants at each site. Randomisation 
lists will be created by the coordinating centre clinical coor-
dinator and accessed online via REDCap database. After 
consenting participants for enrolment and confirming all 
eligibility requirements have been met, the study coordi-
nators who are masked to the allocation sequence assign 
the participants an ID from a predetermined list and will 
log into REDCap and perform the randomisation. The 
now unmasked study coordinators will then give partici-
pants their assigned treatment.
Masking
All study ophthalmologists and participants will remain 
masked to treatment assignment after enrolment. All 
participants will receive both pills and eye drops, and will 
not know which medications are active. Study doctors have 
no part in handling the medication bottles, all participants 
will be given dark bags to place and keep their bottles 
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in throughout the trial. Additionally, participants will 
meet with the study coordinator first, before seeing their 
study doctor at follow- up visits to review the participants’ 
medication calendars, and study coordinators will hold 
participant calendars and study bottles in their office for 
the entire visit. Before bringing participants to the study 
doctor, the study coordinator will remind participants not 
to disclose any information concerning their treatment 
to their study ophthalmologist or any other participants 
they may come across. If the participant is experiencing 
intolerable side effects, the study coordinator and partic-
ipant will speak with the study doctor concerning discon-
tinuation of treatment.
The UCSF pharmacy will be responsible for purchasing 
and distributing bottles of the medications labelled with 
NDC/lot number and expiration dates to the Proctor 
Foundation, and then medications will be distributed to 
all study sites. Study ID labels and dosing instructions will 
be provided to each site on separate label sheets. After 
enrolment and randomisation, each site’s study coordi-
nator will place the study ID label on the bottle, before 
dispensing the drug to the participant. If personnel are 
unmasked at any time, a protocol deviation form must be 
completed.
Intervention
Participants will initially present with anterior uveitis 
suspected to be due to a viral aetiology. Participants will 
receive a routine standard of care work- up for such a 
suspected aetiology, which will include an AC paracen-
tesis.30 Half of this fluid (~50 µL) will be used for qualita-
tive PCR to detect CMV, HSV and VZV at each respective 
site. The other half (~50 µL) will be stored at −80°C. 
Patients will have serologic testing for complete blood 
count, renal function, pregnancy status (in women of 
childbearing age) and HIV status.
In the event a participant is ineligible for study inclu-
sion, the stored 50 µL aliquot will be discarded. In eligible 
participants, this aliquot will undergo quantitative CMV 
PCR at a US laboratory, where laboratory personnel will 
be masked to participant identification, treatment assign-
ment and site. This aliquot will serve as the baseline (prior 
to treatment randomisation) CMV viral load.
Eligible participants will remain masked and 
randomised by the unmasked study site coordinator to 
one of three study treatment arms. After randomisation, 
all participants will receive both tablets and topical eye 
drops. One- third of participants will receive oral valganci-
clovir tablets and placebo eye drops (balanced salt solu-
tion, BSS), one- third will receive topical ganciclovir 2% 
eye drops and placebo tablets, and one- third will receive 
placebo eye drops (BSS) and placebo tablets. Dosing will 
be four tablets daily (900 mg po two times per day) for 
oral medication and six drops per day for topical.
After 7 days of treatment, therapy participants will 
return for clinical examination and repeat AC para-
centesis. Approximately 80 µL will be stored for even-
tual quantitative CMV PCR by the aforementioned US 
laboratory, providing a post- treatment viral load value. 
Approximately 20 µL will be stored for future studies, 
provided a participant provides consent. In addition, 
corneal endothelium will be assessed using confocal or 
specular microscopy (depending on availability of the 
particular imaging modality at each centre) and will be 
used to measure endothelial cell morphology and density 
on day 1 and day 28.
Since it is standard of care to prescribe topical cortico-
steroids to reduce the severity of intraocular inflamma-
tion in participants with anterior uveitis, all participants 
(regardless of randomisation) will be prescribed topical 
prednisolone acetate 1% and instructed to apply one 
drop to the affected eye three times per day. Additionally, 
patients requiring management of elevated intraocular 
pressure (IOP) will be prescribed IOP- lowering medica-
tion according to treating ophthalmologist’s discretion 
and best medical judgement.
Once participants have finished 28 days of treatment, 
including the final clinic visit and evaluation, they will have 
completed the study. The treating ophthalmologist will 
determine whether any continued treatment is necessary. 
Any continued treatment will be based on the treating 
ophthalmologist’s clinical best clinical judgement.
harms and modifications
Non- serious adverse events may include any unfavour-
able medical occurrences in participants who have ever 
received study medication, regardless of any causal rela-
tionship with treatment. This may include increased 
intraocular pressure (>24 mm Hg), abnormal laboratory 
findings (rise in creatinine from ≥1.5 to<2 mg/dL, reduc-
tion of white blood cell count to below >1000 to <2500/
µL, platelet count from 20 000 to 75 000, or haemo-
globin level from >6.5 to <9 g/dL), concurrent accident 
or illness, increase in the frequency and severity of a 
pre- existing condition, side effects intolerable to partic-
ipants (gastrointestinal upset, nausea, vomiting, fatigue), 
or signs of corneal or conjunctival toxicity (keratitis or 
conjunctivitis).23 24 31
If a non- serious adverse event in the form of a labora-
tory abnormality occurs, dose reductions of valganciclovir 
to one tablet (450 mg) two times per day and topical drop 
frequency to three times per day will be made. Repeat 
laboratory testing should be ordered at 7 days of treat-
ment with the reduced dose to monitor for resolution.
Serious adverse events (SAEs) include any medical 
occurrence that results in the following outcomes, 
or any other adverse event classified as severe: creati-
nine≥20 mg/L, leucocytes≤10ˆ9/L, platelets<20*10ˆ9/L, 
haemoglobin<65 g/L, death, non- elective surgery or 
hospitalisation for any reason, myocardial infarction, 
stroke, any life- threatening event, cancer, seizure, 
congenital anomaly/birth defect, disability or permanent 
damage, required intervention to prevent permanent 
impairment/damage.
An unmasked medical monitor will evaluate the details 
of all SAEs via a protocol deviation form and can request 
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additional clinical information and recommend addi-
tional tests. The medical monitor will determine whether 
the event is a true SAE and whether it is likely related 
to the study drug. The medical monitor will recommend 
continuing the study medication versus dose reduction 
versus discontinuation. Additionally, if the investigator 
thinks the SAE is related to the study drug, he/she may 
stop the study medication anytime (including prior to 
evaluation by the medical monitor). Further medical 
management will be at the discretion of the treating 
ophthalmologist and any consulting services. These 
participants should continue with scheduled study visits 
if possible.
All SAEs will require the completion of a protocol devi-
ation form and will be reported to the local institutional 
review board (IRB) and UCSF IRB.
Adherence
Participants will be given a treatment diary in the form of 
a weekly calendar on which they will be asked to record 
adherence as well as reasons for missed doses. At each 
study visit, the study coordinator will review with the partic-
ipant their treatment calendar, and document findings in 
the Medication Log in each participant file. Pill counting 
will also be done for an objective measure of adherence. 
Participants who miss a scheduled dose of medication will 
be instructed to skip that dose and continue with their 
next scheduled dose of tablets or eye drops.
Concomitant care
Study ophthalmologists may use other topical adjunctive 
medications such as IOP- lowering medications and cyclo-
plegic agents. These should be documented on the study 
forms at each visit. The protocol does not allow for intra-
venous, or injection antiviral therapy, additional antivirals 
or surgery during the study period. If such therapies are 
deemed necessary, the protocol deviation form should be 
completed.
Protocol deviation
In rare cases, study ophthalmologists may determine 
that a deviation from protocol is necessary. This is at the 
discretion of the treating ophthalmologist and could be 
undertaken for a variety of reasons including rescue treat-
ment and treatment discontinuation due to intolerability 
or safety. Subjects that experience deviations in treatment 
protocol will continue in their initially assigned treatment 
group and their data will be analysed accordingly.
retention
Participants will be considered to have dropped out from 
the study only if they declare they are no longer inter-
ested in further participation and not willing to return 
for any study visits, or are deceased. If participants are not 
willing to return for any study visits, no further informa-
tion will be collected.
Participants who stop the study treatment for reasons 
other than efficacy, tolerability and/or safety or miss 
study visits and do not respond to contact are considered 
non- compliant participants. Non- compliance will be 
noted and participants will continue their study treatment.
outcome assessments
Viral load reduction
Primary measurement of efficacy of the three treatments 
arms will be a comparison of the log10- transformed quan-
titative viral load PCR at baseline versus after 7 days of 
therapy. This measure provides an objective measure-
ment of treatment efficacy. We note a dearth of published 
data regarding CMV viral loads pretreatment and post- 
treatment. An endpoint of 7 days was chosen as a prior 
study found viral loads to be frequently undetectable 
after 14 days of therapy.32 All quantitative PCR measure-
ments will be conducted at a single laboratory (masked 
to treatment and site) within the USA to ensure the same 
assay will be used on the provided samples, permitting 
direct comparison of quantitative viral load values.
Effect of topical steroids on baseline viral load
Participants will be queried about the frequency of their 
topical steroids use to measure the effect of topical corti-
costeroid use prior to eligibility screening on CMV viral 
load. We anticipate that the dosing of corticosteroids 
prior to presentation or referral will vary depending on 
the practices of the referring physician. More frequent 
dosing of topical corticosteroids may affect the amount 
of virus recovered from the AC perhaps due to local 
immunosuppression.
Clinical response to therapy
For the clinical secondary outcome, participants will be 
classified as ‘quiescent’ if they demonstrate on clinical 
examination: less than or equal to 0.5+AC cell AND reso-
lution of other signs associated with active inflammation, 
including increased IOP, corneal oedema and/or active 
keratic precipitates (KPs). Since active inflammation can 
feature elevated IOP, if IOP is not controlled at a study 
visit, the participant will be considered as ‘not quiescent’. 
This designation, however, does not preclude the partici-
pant from receiving additional IOP- lowering medication 
and the treating ophthalmologist may institute additional 
IOP- lowering medications as deemed necessary. In addi-
tion, a subjective measure of efficacy will be assessed by 
asking participants to estimate how many days after initi-
ating therapy they felt improvement in their symptoms.
Methods: data collection, management and monitoring
Paper forms for each participant will be completed by 
study personnel in real time when the participant is being 
assessed. The forms will be reviewed and cross- checked 
for consistency and completeness by the study coordi-
nator within 24 hours of completion. Study coordina-
tors at all sites will scan data collection forms and send 
them electronically to the Data Coordinating Centre 
(DCC) within 10 days of the participant visit and retain 
hard copies in a secure location. The DCC is responsible 
for supervising data collection, data management, data 
quality control, data analysis, event adjudication, and 
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training and certification of study site staff in the data 
management systems. All data will be entered into the 
official electronic research database, REDCap, within 10 
days of receipt of completed forms.
Discrepancies and missing values will be assessed by the 
data entry manager and resolved by queries sent to the 
study coordinator and appropriate observers. A log file 
will preserve the date and time of any changes, together 
with who entered the changes.
data and safety Monitoring Committee
The Data Safety and Monitoring Committee (DSMC) 
has been established and is independent with experts 
from diverse fields including biostatistics, epidemiology 
and ophthalmology. Only after the DSMC reviews and 
approves the protocol will participants be enrolled. 
The DSMC monitors severe or unexpected events that 
threaten the safety of participants and oversees the data 
collected throughout the duration of the study. The 
DSMC is responsible for reviewing the results of the 
interim analysis and determining whether the trial should 
continue with or without modification.
Patient and public involvement
No patient was involved in the study.
stAtIstICAl AnAlysIs PlAn
sample size
Limited data from the available studies reporting detect-
able CMV viral loads pretreatment and post- treatment 
were available to guide our power calculations. We 
estimate a pretreatment viral load of 5.4 log10IU/
mL6 20 32 33 (SD±1.00 log) and post- treatment viral load 
of 4.88 log10IU/mL
6 32–34 (SD±0.95 log), with correlation 
of 0.7 between baseline and follow- up viral load. With a 
sample size of 33 participants per arm with estimated 10% 
total loss to follow- up, we anticipate at least 80% power to 
detect a 0.61 log difference in viral load (based on pair-
wise analysis subject to an alpha of 0.05/3).
Interim analysis
An interim analysis of efficacy is performed one- third of 
the way through the trial, with alpha set at 0.001. The 
DSMC reviews the unmasked interim analysis and makes 
recommendations on the continuation of the trial. No 
interim analysis for futility is performed. We anticipate 
80% power to detect a difference of 1.7 log units between 
any two arms.
Specific aim 1
The outcome variable is log10 viral load as measured by 
quantitative PCR at 7 days. The primary prespecified anal-
ysis is a permutation p value based on the Fisher F statistic, 
derived from a linear model predicting the log viral load 
(primary outcome variable) as a function of the baseline 
log viral load and the treatment arm (dummy coded), 
that is, analysis of covariance (ANCOVA). Estimation will 
be conducted by ordinary least squares. Type I error rate 
(alpha) of 0.05 will be used.
Quantities of interest for analysis will be quantitative 
PCR data from AC paracentesis aqueous fluid collected 
at the prestudy visit for each participant enrolled in the 
study. The second quantity of interest for comparative 
purposes will be quantitative viral load derived from the 
analysis of aqueous fluid from the second AC paracentesis 
conducted on study day 7 (exam #2). The outcome will 
be modelled as a linear function of baseline value and the 
treatment arm. Specifically, we will test the null hypoth-
esis of a common intercept for all three treatment arms. 
We will also present the change scores for additional 
information and insight.
All quantitative PCR viral loads will be log10- transformed, 
with units converting from IU/mL to log10 IU/mL. The 
baseline quantitative PCR for each participant and treat-
ment will be used as a predictor for quantitative PCR after 
7 days of treatment.
The purpose of supplementary analyses reported in 
this section is to assess the role of statistical choices and 
data quality choices in shaping the result. A Kruskal- Wallis 
non- parametric one- way analysis of variance (ANOVA) 
(using change scores) will be an alternative consideration 
as a statistical analysis choice for the primary outcome. As 
a methodological analysis/sensitivity analysis, we will also 
conduct a Box- Cox transformation of our quantitative 
PCR log transformation.
If the results of the primary analysis are significant, then 
pairwise comparisons based on the Fisher least significant 
difference will be conducted (p values derived by permu-
tation). We will also test for the hypothesis of interaction 
between study country in the two Asian sites (Taiwan and 
Thailand). This will be an assessment of the heterogeneity 
of effect between study sites. In addition, we will repeat 
the primary analysis including an additional random 
effect for study site and report the estimated treatment 
effects under this supplemental model.
Specific aim 2
To compare the proportion of clinical quiescence at day 
7 in the three treatment arms, a logistic regression model 
will be conducted. The outcome variable will be the 
binary classification of quiescence of inflammatory status 
determined by the masked study ophthalmologist. The 
analysis will be two- sided, with a type I error rate (alpha) 
of 0.05/2; the predictor is the study arm (as a factor). In 
addition, we will repeat this analysis for data collected on 
day 28. We propose a Bonferroni correction, for an alpha 
of 0.05/2. We will also tabulate the number of individuals 
who change status, reporting the 2×2 table of day 7 versus 
day 28 status, by arm. Missing data will be reported, and a 
sensitivity analysis will be conducted to assess the degree 
to which missing data could have affected the findings. 
Data collected at ±2 days will be used (day 7 data can 
be collected between days 5–9, and day 28 data can be 
collected at 26–30 days).
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Table 5 Trial registration data and protocol summary
Data category Information
Primary registry and trial identifying number ClinicalTrials.gov
NCT03576898
Date of registration in primary registry 3 July 2018
Secondary identifying numbers   
Source of monetary or material support Francis I. Proctor Foundation, University of California, San Francisco
Contact for queries John A. Gonzales, MD (john.gonzales@ucsf.edu)
Title Systemic and Topical Antiviral Control of Cytomegalovirus Anterior uveitis: 
Treatment Outcomes
Countries of recruitment Thailand, Taiwan, USA
Health condition or problem studied Cytomegalovirus anterior uveitis treatment
Intervention(s) Intervention: treating with 900 mg two times per day of oral valganciclovir, or 
topical 2% ganciclovir solution q2h for a duration of 28 days
Control: placebo tablets and eyedrops
Key eligibility criteria CMV positive anterior chamber paracentesis, active signs of anterior uveitis, no 
history of immunodeficiency, normal laboratory values for CBC and renal function
Study type Competitive block randomised, placebo controlled clinical trial
Date of first enrolment N/A
Target sample size 99 to 33 per treatment arm
Primary outcome Change in log- transformed viral load
Key secondary outcomes Objective and subjective time to achieve clinical quiescence, and the relationship 
of topical steroid strength and dosing on initial anterior chamber paracentesis 
quantitative viral load for CMV
Project timeline July 2019–August 2021
CMV, cytomegalovirus.
Participants will also be administered a questionnaire 
querying when they felt symptomatic improvement other 
their condition. This analysis will be viewed as hypothesis 
generating and will be treated as supplementary and in 
addition to the main finding.
Nested observational aim
To assess the observational effect of topical corticoste-
roid administered prior to study enrolment on diagnostic 
yield of quantitative PCR, an ANCOVA of log- transformed 
mean viral load at initial AC paracentesis versus frequency 
of prestudy topical steroid use will be conducted. The 
analysis will be two- sided with a type I error rate (alpha) of 
0.05. We will report the findings unadjusted as hypothesis 
generating for a future larger trial. This will be sharply 
demarcated from the primary analysis. Bonferroni- Holm 
correction will be considered for this sub- aim.
Secondary analyses
In addition, an efficacy analysis will be conducted in 
which we include phenotype as a binary predictor (and 
the interaction with treatment). Phenotype of CMV 
anterior uveitis will be determined by the masked study 
ophthalmologist (acute/recurrent vs chronic). Anal-
ysis will consist of an ANCOVA as before, with the addi-
tional covariates. We will perform a hypothesis test of the 
coefficient for the phenotype–treatment interactions, 
two- sided, with a type I error rate (alpha) of 0.05.
Individual level missing data (due to loss to follow- up or 
dropouts) is expected. Complete analysis will be reported. 
Missing values will be tabulated by treatment arm and 
study site. Sensitivity analysis assigning outcomes to the 
missing values will be reported. Additionally, analyses will 
be reported in which we adjust for any baseline covariate 
known to be a predictor of missing outcome data.
EthICs And dIssEMInAtIon
This protocol and informed consent forms have been 
approved by the IRB at the University of California, San 
Francisco and Khon Kaen University. The trial is regis-
tered at  clinicaltrials. gov (NCT03576898). Protocol 
modifications are submitted to the relevant parties for 
review and/or approval. Subsequent to initial review and 
approval, the responsible local IRB/ethics committees 
(ECs) will review the protocol annually. The investigators 
will make safety and progress reports to the IRBs/ECs at 
least annually and within 3 months of study termination 
or completion at their site. These reports will include the 
total number of participants enrolled, adverse events and 
summaries of each DSMC review of safety and/or efficacy 
meeting. On completion of the 28- day study treatment 
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protocol, the participant’s treatment plan can be modi-
fied in any way the participant’s ophthalmologist feels fit.
Written consent will be obtained for all study proce-
dures after explaining the patient’s disease, prognosis 
and treatment options, discussing the risks and benefits of 
participation, and addressing the patient’s questions and 
concerns. The protocol site- specific informed consent 
forms in local language (Thai, Chinese or English), 
participant education and recruitment materials, other 
requested documented and any subsequent modifica-
tions shall also be reviewed and approved by the ethical 
review bodies at each respective site. Table 5 summarises 
the study protocol and trial registration information.
Only key study personnel will have access to identifying 
information of participants, while administrative forms 
and specimens will be deidentified.
A portion of biological samples from the second AC 
paracentesis (approximately 20 µL of aqueous fluid) will 
be obtained for use in a future study of virus genome 
assay. A consent will be obtained and included in the 
main study consent form to specifically address the collec-
tion and future studies of such aqueous fluid.
The results of this trial will be presented at local and 
international meetings and submitted to peer- reviewed 
journals for publication.
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